Form 8-K PTC THERAPEUTICS, INC. For: Jun 21
- Wall St opens flat ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
PTC Therapeutics (PTCT) PT Raised to $46 at RBC Capital
June 23, 2022 5:17 AM EDTRBC Capital analyst Brian Abrahams raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $42.00) while maintaining a Sector Perform rating.
The analyst comments "Following this week's ph.III Study 041 data, we have made updates to our model including increasing from 80% to... More
PTC Therapeutics (PTCT) PT Lowered to $45 at Cowen
June 21, 2022 4:12 PM EDTCowen analyst Joseph Thome lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $48.00) while maintaining a Market Perform rating after the company announced results of Translarna's Study 041 this morning.
The analyst commented, "Based on our conversations with management... More
Raymond James Offers Thoughts on PTC Therapeutics (PTCT)
June 21, 2022 2:37 PM EDTRaymond James analyst Danielle Brill reiterated an Outperform rating and {REMOVEPT} price target on PTC Therapeutics (NASDAQ: PTCT).
The analyst comments "While ITT data should generally outweigh a subgroup analysis, here ITT was not the prespecified primary population of interest (so p-value might be nominal). Its also unclear what biases might exist for patients enrolled in the trial with baseline metrics that precluded them from being... More
Credit Suisse on PTC Therapeutics (PTCT): 'we continue to employ a wait-and-see approach for Translarna in the U.S'
June 21, 2022 1:12 PM EDTCredit Suisse analyst Judah C. Frommer reiterated a Neutral rating and $51.00 price target on PTC Therapeutics (NASDAQ: PTCT).
The analyst comments "PTC this morning released topline data from Study 041, the companys Ph3 placebo-controlled trial of Translarna in nonsense mutation DMD patients, ahead of the companys presentation at PPMDs... More
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT), 'Upside Remains on Raised Full EU Approval Outlook'
June 21, 2022 11:34 AM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating on PTC Therapeutics (NASDAQ: PTCT)
The analyst comments "On the whole, we view this mornings top-line Study 041 results as a win for Translarna and PTCT shares. While technically failing on the primary endpoint of 6MWD in the primary subgroup population (patients with 300m and 5m supine to stand at baseline; n~185), Translarna demonstrated significant 6MWD benefit over... More
RBC Capital on PTC Therapeutics (PTCT): 'Data Should Be Good Enough for Translarna to Stay on EU Mkt'
June 21, 2022 9:40 AM EDTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $42.00 price target on PTC Therapeutics (NASDAQ: PTCT)
The analyst comments "This morning, PTCT revealed data from the ph.III confirmatory Study 041 of Translarna in DMD with nonsense mutations, which was... More
PTC Therapeutics (PTCT) Releases Copy of Slide Deck on Trial of Study 041 for Translarna
June 21, 2022 8:37 AM EDTPTC Therapeutics (NASDAQ: PTCT) disclosed:
As previously announced, PTC Therapeutics, Inc. (the Company) hosted a conference call on June 21, 2022 at 8:00 a.m. eastern time. During this conference call, the Company discussed the top-line results from the placebo-controlled trial of Study 041 for... More